Participants 251 271 4
patients with cancer
Participants 427 463 3
opioid-tolerant patients with cancer
Participants 580 652 5
opioid-tolerant male and female patients (aged > or =17 years) with BTcP
Participants 1412 1511 5
131 patients entered the titration phase, of whom 61 were included in the primary efficacy analysis
Participants 2546 2582 3
opioid-tolerant patients with cancer
